DUBLIN, April 27, 2020 /PRNewswire/ -- The "Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This pipeline guide ...
Reports for the use of steroids in the management of proliferative vitreoretinopathy (PVR) are inconsistent. The advent of a sustained-release implant that can release dexamethasone for 3-4 months in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback